# US 2025/0144025 A1 · Anti-abuse gelled pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144025 A1
- Document ID: US20250144025A1
- Status: Published application
- Kind: A1
- Application number: 18/737,628
- Filed: 2024-06-07
- Published: 2025-05-08
- Earliest claimed: 2010-04-14
- Assignees: Vitux Group AS
- Applicants: Vitux Group AS
- Inventors: Kurt Ingar Draget; Ingvild Johanne Haug; Steinar Johan Engelsen; Tore Seternes; Magnus N. Hattrem
- Web page: https://patentgrep.com/patent/US20250144025A1

## CPC

- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides an oral pharmaceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion containing a drug of abuse.

## Claims

### Claim 1

A pharmaceutical composition comprising a physiologically tolerable, flexible, gelled biphasic oil-in-water emulsion containing a drug of abuse which is in a non-prodrug form and which is selected from the group consisting of codeine, morphine, morphine-6-glucuronide, hydrocodone, oxycodone, diamorphine, pethidine, tramadol, buprenorphine, propoxyphene, dextropropoxyphene, hydromorphone, oxymorphone, pentazocine, levorphanol, butorphanol, ketobemidone, fentanyl, meperidine, diphenoxylate, venlafaxine, nefopam, carbamazepine, gabapentin, pregabalin, amitryptiline, pentobarbital sodium, diazepam, alprazolam, flunitrazepam, amphetamine, l-lysine-d-amphetamine, methyl phenidate, methadone, mephedrone, tetrahydrocannabinol, ketamine, clonidine, mexiletine, and tapentadol;
wherein said composition is in oral, uncoated dose unit form and said dose unit has a weight of 50 to 3000 mg; and
wherein said emulsion has an oil phase and an aqueous phase, said oil phase including a physiologically tolerable lipid, and said aqueous phase including water and a physiologically tolerable gelling agent; and
wherein the weight ratio of the oil phase to the aqueous phase of the emulsion is 1:19 to 3:1.

### Claim 2 (depends on 1)

A method of treatment of a human subject by oral administration to said subject of an effective amount of a drug substance which is a drug of abuse, comprising the step of administering said drug substance in pharmaceutical composition according to claim 1.

### Claim at position 3

3-7. (canceled)

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the drug of abuse is in dissolved or dispersed form.

### Claim 9 (depends on 1)

The composition according to claim 1, further comprising an unsaturated fatty acid.

### Claim 10 (depends on 1)

The composition according to claim 1, further comprising an additional component selected from lipids, vitamins, minerals, folic acid, pH modifiers, viscosity modifiers, flavours, aromas, sweeteners, colorants and antioxidants.

### Claim 11 (depends on 1)

The composition according to claim 1, further comprising a citrus flavour.

### Claim 12 (depends on 1)

The composition according to claim 1, further comprising xylitol.

### Claim 13 (depends on 1)

The composition according to claim 1, wherein said weight ratio is 35:65 to 1:1.

### Claim 14 (depends on 1)

The composition according to claim 1, wherein said weight ratio is 2:3 to 1:1.

### Claim 15 (depends on 1)

The composition according to claim 1, wherein said dose unit is individually packaged.

### Claim 16 (depends on 1)

The composition according to claim 1, wherein said drug of abuse is in said oil phase.

### Claim 17 (depends on 1)

The composition according to claim 1, wherein said drug of abuse is in said aqueous phase.

### Claim 18

A method of preventing abuse of a drug substance which is a drug of abuse, said method comprising the step of formulating said drug substance in a physiologically tolerable gelled oil-in-water emulsion.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said drug substance is formulated in a pharmaceutical composition comprising a physiologically tolerable, flexible, gelled biphasic oil-in-water emulsion containing said drug of abuse which is in a non-prodrug form and which is selected from the group consisting of codeine, morphine, morphine-6-glucuronide, hydrocodone, oxycodone, diamorphine, pethidine, tramadol, buprenorphine, propoxyphene, dextropropoxyphene, hydromorphone, oxymorphone, pentazocine, levorphanol, butorphanol, ketobemidone, fentanyl, meperidine, diphenoxylate, venlafaxine, nefopam, carbamazepine, gabapentin, pregabalin, amitryptiline, pentobarbital sodium, diazepam, alprazolam, flunitrazepam, amphetamine, l-lysine-d-amphetamine, methyl phenidate, methadone, mephedrone, tetrahydrocannabinol, ketamine, clonidine, mexiletine, and tapentadol;
wherein said composition is in oral, uncoated dose unit form and said dose unit has a weight of 50 to 3000 mg; and
wherein said emulsion has an oil phase and an aqueous phase, said oil phase including a physiologically tolerable lipid, and said aqueous phase including water and a physiologically tolerable gelling agent; and
wherein the weight ratio of the oil phase to the aqueous phase of the emulsion is 1:19 to 3:1.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the pharmaceutical composition comprises said drug of abuse in dissolved or dispersed form.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the pharmaceutical composition further comprises an unsaturated fatty acid.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the pharmaceutical composition further comprises an additional component selected from lipids, vitamins, minerals, folic acid, pH modifiers, viscosity modifiers, flavours, aromas, sweeteners, colorants and antioxidants.

### Claim 23 (depends on 19)

The method according to claim 19, wherein the pharmaceutical composition further comprises a citrus flavour.

### Claim 24 (depends on 19)

The method according to claim 19, wherein the pharmaceutical composition further comprises xylitol.

### Claim 25 (depends on 19)

The method according to claim 19, wherein said weight ratio is 35:65 to 1:1.

### Claim 26 (depends on 19)

The method according to claim 19, wherein said weight ratio is 2:3 to 1:1.

### Claim 27 (depends on 19)

The method according to claim 19, wherein said dose unit is individually packaged.

### Claim 28 (depends on 19)

The method according to claim 19, wherein the pharmaceutical composition comprises said drug of abuse in said oil phase.

### Claim 29 (depends on 19)

The method according to claim 19, wherein the pharmaceutical composition comprises said drug of abuse in said aqueous phase.
